UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 17, 2015
OXFORD IMMUNOTEC GLOBAL PLC
(Exact name of registrant as specified in its charter)
England and Wales
(State or other jurisdiction
of incorporation)
|
001-36200 |
|
98-1133710 |
|
(Commission |
|
(IRS Employer |
94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom
(Address of principal executive offices)
Registrant’s telephone number including area code +44 (0) 1235 442780
Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 17, 2015 the Remuneration Committee of the Board of Directors of Oxford Immunotec Global PLC adjusted the salaries of the Company’s named executive officers and the target bonus percentage for the chief executive officer, Dr. Peter Wrighton-Smith, for 2015. These changes are described in the following table.
|
Named Executive Officer |
Base Salary for 2015 |
Target Bonus Percentage for 2015 |
|
Peter Wrighton-Smith, Ph.D. |
£280,000 |
70% |
|
Jeff R. Schroeder |
$334,000 |
50% |
|
Peter Edwardson, Ph.D. |
£198,000 |
50% |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 22, 2015
|
OXFORD IMMUNOTEC GLOBAL PLC | ||
|
By: |
|
/s/ Richard M. Altieri |
|
|
Richard M. Altieri | |
|
|
Chief Financial Officer | |